A Novel Micro-Linear Vector for In Vitro and In Vivo Gene Delivery and Its Application for EBV Positive Tumors

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wang, Hong Sheng ^a   Chen, Zhuo Jia ^a   Zhang, Ge ^a   Ou, Xue Ling ^b   Yang, Xiang Ling ^a   Wong, Chris K C ^c   Giesy, John P ^d   Du, Jun ^a   Chen, Shou Yi ^e  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; GANCICLOVIR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; OLIGODEOXYNUCLEOTIDE; PLASMID VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA TEMPLATE; DNA VECTOR; EPSTEIN BARR VIRUS; EUKARYOTE; FEMALE; GENE; GENE AMPLIFICATION; GENE CASSETTE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; INFLAMMATION; MALE; MICRO LINEAR VECTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1 GENE; MOUSE; NEOPLASM; NONHUMAN; POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; CYTOKINES; GENETIC THERAPY; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; MALE; MAP KINASE KINASE KINASE 1; MICE; MICE, INBRED BALB C; NEOPLASMS; PLASMIDS; TRANSFECTION;

EID: 84867537316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047159     Document Type: Article

References (37)

1. Schmidt-Wolf GD, Schmidt-Wolf IGH, (2003) Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med 9: 67-72.
2. Glover DJ, Lipps HJ, Jans DA, (2005) Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6: 299-310.
3. Nishikawa M, Hashida M, (2002) Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Bio Pharm Bull 25: 275-283.
4. Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N, (2005) Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 78: 647-655.
5. Darquet AM, Rangara R, Kreiss P, Schwartz B, Naimi S, et al. (1999) Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 6: 209-218.
6. Johansson P, Lindgren T, Lundstrom M, Holmstrom A, Elgh F, et al. (2002) PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine. Vaccine 20: 3379-3388.
7. Chang CW, Christensen LV, Lee M, Kim SW, (2008) Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy. J Control Release 125: 155-163.
8. Reyes-Sandoval A, Ertl HCJ, (2004) CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther 9: 249-261.
9. Chen ZY, He CY, Kay MA, (2005) Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 16: 126-131.
10. Schakowski F, Gorschluter M, Junghans C, Schroff M, Buttgereit P, et al. (2001) A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3: 793-800.
11. Machelska H, Schroff M, Oswald D, Binder W, Sitte N, et al. (2009) Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain. Mol Pain 5: 72.
12. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, Sack F, Moreno S, et al. (2002) DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21: 247-257.
13. Zheng C, Juhls C, Oswald D, Sack F, Westfehling I, et al. (2006) Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. Vaccine. 24: 4625-4629.
14. Schakowski F, Gorschluter M, Buttgereit P, Marten A, Lilienfeld-Toal MV, et al. (2007) Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo 21: 17-23.
15. Hofman CR, Dileo JP, Li Z, Li S, Huang L, (2001) Efficient in vivo gene transfer by PCR amplified fragment with reduced inflammatory activity. Gene Ther 8: 71-74.
16. Hirata K, Nishikawa M, Kobayashi N, Takahashi Y, Takakura Y, (2007) Design of PCR-amplified DNA fragments for in vivo gene delivery: Size-dependency on stability and transgene expression. J Pharm Sci 96: 2251-2261.
17. Xu X, Yang Z, Liu Q, Wang Y, (2010) In vivo fluorescence imaging of muscle cell regeneration by transplanted EGFP-labeled myoblasts. Mol Ther 18: 835-842.
18. He YW, Cai SH, Zhang G, Li XQ, Pan LT, et al. (2008) Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. Virus Res 135: 175-180.
19. Esin S, Batoni G, Kallenius G, Gaines H, Campa M, et al. (1996) Proliferation of distinct human T cell subsets in response to live, killed or soluble extracts of Mycobacterium tuberculosis and Mycoavium. Clin Exp Immunol 104: 419-425.
20. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, et al. (2009) Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med 11: 435-443.
21. Yoshida H, Nishikawa M, Yasuda S, Mizuno Y, Takakura Y, (2008) Cellular activation by plasmid DNA in various macrophages in primary culture. J Pharm Sci 97: 4575-4585.
22. Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y, (2005) Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and-independent pathways. J Leukoc Biol 77: 71-79.
23. Zhang X, Epperly MW, Kay MA, Chen ZY, Dixon T, et al. (2008) Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther 19: 820-826.
24. Chen ZY, He CY, Ehrhardt A, Kay MA, (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8: 495-500.
25. Nakai H, Montini E, Fuess S, Storm TA, Meuse L, et al. (2003) Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol Ther 7: 101-111.
26. Chen ZY, Yant SR, He CY, Meuse L, Shen S, et al. (2001) Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther 3: 403-410.
27. Kameda S, Maruyama H, Higuchi N, Nakamura G, Iino N, et al. (2003) Hydrodynamics-based transfer of PCR-amplified DNA fragments into rat liver. Biochem Biophys Res Commun 309: 929-936.
28. Ludtke JJ, Zhang GF, Sebestyen MG, Wolff JA, (1999) A nuclear localization signal can enhance both the nuclear transport and expression of 1 kb DNA. J Cell Sci 112: 2033-2041.
29. Hagstrom JE, Ludtke JJ, Bassik MC, Sebestyen MG, Adam SA, et al. (1997) Nuclear import of DNA in digitonin-permeabilized cells. J Cell Sci 110: 2323-2331.
30. Kako K, Nishikawa M, Yoshida H, Takakura Y, (2008) Effects of inflammatory response on in vivo transgene expression by plasmid DNA in mice. J Pharm Sci 97: 3074-3083.
31. Tan Y, Li S, Pitt BR, Huang L, (1999) The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 10: 2153-2161.
32. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, et al. (2004) Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 6: 395-404.
33. Grewal SI, Moazed D, (2003) Heterochromatin and epigenetic control of gene expression. Science 301: 798-802.
34. de Wolf HK, Johansson N, Thong AT, Snel CJ, Mastrobattista E, et al. (2008) Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes. Pharm Res 25: 1654-1662.
35. Wilson KD, de Jong SD, Tam YK, (2009) Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev 61: 233-242.
36. Li HP, Leu YW, Chang YS, (2005) Epigenetic changes in virus-associated human cancers. Cell Res 15: 262-271.
37. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.